Bartolomé Vilanova

Prof. Dr. Bartolomé Vilanova

orcid

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in Biomacromolecules
Verified
Journal Article
Closed access
AMAdrover Miquel
Adrover Miquel
LMLaura Mariño
Laura Mariño
PSPilar Sanchis
Pilar Sanchis
KPKris Pauwels
Kris Pauwels
YKYvonne Kraan
Yvonne Kraan
JDJosefa Donoso
Josefa Donoso

1 September 2019 in Antioxidants
Verified
Journal Article
Open access
PDF file
RRRafael Ramis
Rafael Ramis
JOJoaquin Ortega-Castro
Joaquin Ortega-Castro
CCCarmen Caballero
Carmen Caballero
RCRodrigo Casasnovas
Rodrigo Casasnovas
ACAntonia Cerrillo
Antonia Cerrillo
JFJuan Frau
Juan Frau
Pyridoxamine, one of the natural forms of vitamin B6, is known to be an effective inhibitor of the formation of advanced glycation end products (AGEs), which are closely related to various human diseases. Pyridoxamine forms stable complexes with metal ions that catalyze the oxidative reactions taking place in the advanced stages of the protein glycation cascade. It also reacts with reactive carbonyl compounds generated as byproducts of protein glycation, thereby preventing further protein damage. We applied Density Functional Theory to study the primary antioxidant activity of pyridoxamine towards three oxygen-centered radicals (•OOH, •OOCH3 and •OCH3) to find out whether this activity may also play a crucial role in the context of protein glycation inhibition. Our results show that, at physiological pH, pyridoxamine can trap the •OCH3 radical, in both aqueous and lipidic media, with rate constants in the diffusion limit (>1.0 × 108 M − 1 s − 1 ). The quickest pathways involve the transfer of the hydrogen atoms from the protonated pyridine nitrogen, the protonated amino group or the phenolic group. Its reactivity towards •OOH and •OOCH3 is smaller, but pyridoxamine can still scavenge them with moderate rate constants in aqueous media. Since reactive oxygen species are also involved in the formation of AGEs, these results highlight that the antioxidant capacity of pyridoxamine is also relevant to explain its inhibitory role on the glycation process.

1 April 2019 in Journal of Chemical Information and Modeling
Verified
Journal Article
Closed access
RRRafael Ramis
Rafael Ramis
JOJoaquin Ortega-Castro
Joaquin Ortega-Castro
RCRodrigo Casasnovas
Rodrigo Casasnovas
LMLaura Mariño
Laura Mariño
BVBartolomé Vilanova
Bartolomé Vilanova
JFJuan Frau
Juan Frau

1 May 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
AMAdrover Miquel
Adrover Miquel
BVBartolomé Vilanova
Bartolomé Vilanova
JFJuan Frau
Juan Frau
FMFrancisco Muñoz
Francisco Muñoz
JDJosefa Donoso
Josefa Donoso

14 July 2015 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LMLaura Mariño
Laura Mariño
KPKris Pauwels
Kris Pauwels
RCRodrigo Casasnovas
Rodrigo Casasnovas
PSPilar Sanchis
Pilar Sanchis
BVBartolomé Vilanova
Bartolomé Vilanova
AMAdrover Miquel
Adrover Miquel
Protein aggregation with the concomitant formation of amyloid fibrils is related to several neurodegenerative diseases, but also to non-neuropathic amyloidogenic diseases and non-neurophatic systemic amyloidosis. Lysozyme is the protein involved in the latter and it is widely used as a model system to study the mechanisms underlying fibril formation and its inhibition. Several phenolic compounds have been reported as inhibitors of fibril formation. However, the anti-aggregating capacity of other heteroaromatic compounds has not been studied in any depth. We have screened the capacity of eleven different hydroxypyridines to affect the acid-induced fibrillization of hen lysozyme. Although most of the tested hydroxypyridines alter the fibrillation kinetics of HEWL, only 3-hydroxy-2-methylpyridine, 3-hydroxy-6-methylpyridine and 3-hydroxy-2,6-dimethylpyridine completely abolish fibril formation. Different biophysical techniques and several theoretical approaches are combined to elucidate their mechanism of action. O-methylated 3-hydroxypyridines bind non-cooperatively to two distinct but amyloidogenic regions of monomeric lysozyme. This stabilises the protein structure, as evidenced by enhanced thermal stability and results in the inhibition of the conformational transition that precedes fibril assembly. Our results point to o-methylated 3-hydroxypyridines as a promising molecular scaffold for the future development of novel fibrillization inhibitors.

10 March 2020 in Chemical Science
Verified
Journal Article
Open access
PDF file
LMLaura Mariño
Laura Mariño
RRRafael Ramis
Rafael Ramis
RCRodrigo Casasnovas
Rodrigo Casasnovas
JOJoaquin Ortega-Castro
Joaquin Ortega-Castro
BVBartolomé Vilanova
Bartolomé Vilanova
AMAdrover Miquel
Adrover Miquel
We study the effect of an advanced glycation end product ( N (ε)-(carboxyethyl)lysine), found on the Lewy bodies of people suffering from Parkinson’s disease, on the conformational and aggregation features of alpha-synuclein.